Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: A review of the empirical evidence

American Journal of Drug and Alcohol Abuse

Volumn 33, Issue 5, 2007, Pages 643-654

  Copenhaver, Michael M ^a   Bruce, R Douglas ^b   Altice, Frederick L ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

Behavioral counseling; Buprenorphine; Cognitive behavioral therapy; Motivational enhancement techniques; Motivational interviewing; Opioid dependence; Substance abuse treatment

Indexed keywords

BUPRENORPHINE; ILLICIT DRUG;

BEHAVIORAL RESEARCH; COGNITIVE THERAPY; COMMUNITY HEALTH NURSING; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; EMPIRICISM; HUMAN; MOTIVATION; PATIENT COUNSELING; PREVENTIVE MEDICINE; REVIEW; TREATMENT OUTCOME; UNITED STATES;

ADAPTATION, PSYCHOLOGICAL; BUPRENORPHINE; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; COUNSELING; HUMANS; METHADONE; MOTIVATION; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; PATIENT DROPOUTS; RECURRENCE; SUBSTANCE ABUSE TREATMENT CENTERS; TREATMENT OUTCOME; UNITED STATES;

EID: 34648829826     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.1080/00952990701522674     Document Type: Review

References (36)

1. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: mplications and management for clinical practice. J Acquir Immune Defic Syndr 2006; 41(5):563-572.
2. Feillin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat 2004; 27:153-159.
3. Rosenheck R, Kosten T. Buprenorphine for opiate addiction: potential economic impact. Drug Alcohol Depend 2001; 63(3):253-262.
4. Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98(4):441-452.
5. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343:1290-1297.
6. Rounsaville BJ, Kleber HD. Untreated opiate addicts: how do they differ from those seeking treatment? Arch Gen Psychiatry 1985; 43:739-745.
7. Montoya ID, Schroeder JR, Preston KL, Covi L, Umbricht A, Contoreggi C, Fudala PJ, Johnson RE, Gorelick DA. Influence of psychotherapy attendance on buprenorphine treatment outcome. J Subst Abuse Treat 2005; 28:247-254.
8. Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, Lange WR, Contoreggi C, Johnson RE, Fudala PJ. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 2004; 75:34-48.
9. Kosten TR, O'Connor PG. Current concepts - management of drug withdrawal. N Engl J Med 2003; 348:1786-1795.
10. U.S. Dept of Health and Human Services Publication No. (SMA) 04-3939. TIP 40. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment; 2004.
11. Feillin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, Schottenfeld RS. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006; 355:365-374.
12. Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, Brigham G, Harrer J, Reid M, Muir J, Buchan B, Orr D, Woody G, Krejci J, Ziedonis D, the Buprenorphine Study Protocol Group. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the national institute on drug abuse clinical trials network. Addiction 2005; 100:1090-1100.
13. O'Connor PG, Oliveto AH, Shi JM, Triffleman EG, Carroll KM, Kosten TR, Rounsaville BJ, Pakes JA, Schottenfeld RS. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med 1998; 105:100-105.
14. Margolin A, Avants SK, Warburton LA, Hawkins KA. Factors affecting cognitive functioning in a sample of human immunodeficiency virus-positive injection drug users. AIDS Pat Care STDs 2002; 16(6):255-267.
15. Schottenfeld RS, Pakes J, O'Connor P, Chawarski M, Oliveto A, Kosten T. Thrice-weekly versus daily buprenorphine maintenance. Biol Psychiatry 2000; 11:1072-1079.
16. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med 2005; 20:1038-1041.
17. Sofuoglu M, Gonzalez G, Poling J, Kosten TR. Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence. Am J Drug Alcohol Abuse 2003; 29(4):713-727.
18. Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, Banys P, Hall SM. Methadone maintenance vs. 180-day psychosocially enriched detoxification treatment of opioid dependence: a randomized controlled trial. JAMA 2006; 283(10):1303-1310.
19. George W, Joe D, Simpson D, Broome KM. Effects of readiness for drug abuse treatment on client retention and assessment of process. Addiction 1998; 93(8):1177-1187.
20. Carroll KM, Ball SA, Nich C, Martino S, Frankforter TL, Farentinos C, Kunkel LE, Mikulich-Gilbertson SK, Morgenstern J, Obert JL, Polcin D, Snead N, Woody GE. Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: a multi-site effectiveness study. Drug Alcohol Depend 2006; 81(3):301-312.
21. Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change. 2nd ed. New York: Guilford Press, 2002.
22. Rothenberg JL, Sullivan MA, Church SH, Seracini A, Collins E, Kleber HD, Nunes EV. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat 2002; 23:351-360.
23. Linehan MM, Dimeff LA, Reynolds SK, Comtois A, Welch SS, Heagerty P, Kivlahan DR. Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend 2002; 67:13-26.
24. Fisher JD, Cornman DH, Osborn CY, Amico KR, Fisher WA, Friedland GH. Clinician-initiated HIV risk reduction intervention for HIV-positive persons: formative research, acceptability, and fidelity of the OPTIONS project. JAIDS 2004; 37:S78-S87.
25. Project MATCH Research Group. Matching alcoholism treatments to client heterogeneity: project MATCH three-year drinking outcomes. Alcohol: Clin Exper Res 1998; 22:1300-1311.
26. Rollnick S, Butler C, Stott N. Helping smokers make decisions: the enhancement of brief intervention for general medical practice. Patient Educ Couns 1997; 31:191-203.
27. Petry NM, Simcic F, Jr. Recent advances in the dissemination of contingency management techniques: Clinical and research perspectives. J Subst Abuse Treat 2002; 23:81-86.
28. Scherbaum N, Kluwig J, Specka M, Krause D, Merget B, Finkbeiner T, Gastpar M. Group psychotherapy for opiate addicts in methadone maintenance treatment - a controlled trial. Eur Addict Res 2005; 11:163-171.
29. Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirtz PW, Gawin, FH. One year follow-up of psychotherapy and pharmacotherapy for cocaine dependence: delayed emergence of psychotherapy effects. Arch Gen Psychiatry 1994; 51:989-997.
30. Carroll KM, Sinha R, Nich C, Babuscio T, Rounsaville BJ. Contingency management to enhance naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement magnitude. Exper Clin Psychopharm 2002; 10:54-63.
31. Carroll KM, Nich C, Ball SA, Mc Cane E, Frankforter TL, Rounsaville BJ. One year follow-up of disulfiram and psychotherapy for cocaine-alcohol abusers: Sustained effects of treatment. Addiction 2000; 95:1335-1349.
32. Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin Infect Dis 2006; 43(Suppl 4):S178-83.
33. Carroll KM, Nich C, Ball SA, McCance E, Rounsaville BJ. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998; 93:713-728.
34. Copenhaver M, Lee IC, Harman J, Johnson BT, Carey, M. Behavioral HIV risk reduction among injection drug users: meta-analytic evidence of efficacy. J Subst Abuse Treat 2006; 31:163-171.
35. Copenhaver M, Lee IC, Margolin A. Successfully integrating an HIV risk reduction intervention into a community-based substance abuse treatment program. Am J Drug Alcohol Abuse 2007; 33(1):109-120.
36. Basu S, Smith-Rohrberg D, Bruce RD, Altice FL. Models for integrating buprenorphine therapy into HIV care. Clin Infect Dis 2006; 42:716-721.